6th Edition of Cardiology World Conference
September 15-17, 2025 | London, UK
Angiotensin Receptor Blockers
Angiotensin Receptor Blockers (ARBs) play a crucial role in the field of cardiovascular medicine by targeting the renin-angiotensin-aldosterone system. These medications, also known as angiotensin II receptor antagonists, work by blocking the action of angiotensin II on specific receptors, thereby dilating blood vessels and reducing the workload on the heart. ARBs are commonly prescribed to manage conditions such as hypertension, heart failure, and diabetic nephropathy. By modulating the effects of angiotensin II, ARBs contribute to blood pressure regulation and the overall well-being of individuals with cardiovascular concerns. Their distinct mechanism of action and efficacy make ARBs a valuable class of drugs in the therapeutic arsenal against cardiovascular diseases, offering patients a targeted and effective approach to managing their health.
Yong Xiao Wang
Albany Medical Center, United States
Robert J Chilton
University of Texas Health Science Center San Antonio, United States
Gustavo Lionel Knop
Mayo Clinic, United States
Arthur J Siegel
Massachusetts General Hospital, United States
Abraham Teddy Weiss
Hadassah University Hospital, Israel
Narendra Kumar
HeartbeatsZ Academy, United Kingdom
Iris Panagiota Efthymiou
University of Greenwich, United KingdomSubmit your abstract Today
Title : Novel ways of cardiovascular risk assessment
Syed Raza, Awali Hospital, Bahrain
Title : Preventing sports-related cardiac arrest: Coronary artery calcium scoring stratifies the benefit of low-dose aspirin use for risk reduction
Arthur J Siegel, Massachusetts General Hospital, United States
Title : Empathy and precision: Revolutionizing communication between cardiologists and patients
Iris Panagiota Efthymiou, University of Greenwich, United Kingdom
Title : Ex-situ organ perfusion and cardiac performance improvement
Y J H J Taverne, Erasmus University Medical Center, Netherlands
Title : Subclinical atherosclerosis: Association with additional risk factors and somatic diseases
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : The past, present and future of AI in cardiology
Narendra Kumar, HeartbeatsZ Academy, United Kingdom